Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 478Carcinoma, Non-Small-Cell Lung 436Prostatic Neoplasms 277Lung Neoplasms 169Stomach Neoplasms 138Neoplasms 112Squamous Cell Carcinoma of Head and Neck 108Head and Neck Neoplasms 96Neoplasm Metastasis 92Esophageal Neoplasms 70Ovarian Neoplasms 56Pancreatic Neoplasms 41Sarcoma 39Urinary Bladder Neoplasms 38Nasopharyngeal Carcinoma 32Carcinoma, Squamous Cell 30Triple Negative Breast Neoplasms 28Carcinoma, Ovarian Epithelial 28Adenocarcinoma of Lung 27Adenocarcinoma 27Esophageal Squamous Cell Carcinoma 25Parkinson Disease 4, Autosomal Dominant Lewy Body 23Carcinoma, Transitional Cell 23Adenocarcinoma Of Esophagus 23Breast Neoplasms, Male 22Recurrence 21Unspecified Adult Solid Tumor, Protocol Specific 20Inflammatory Breast Neoplasms 20Fallopian Tube Neoplasms 20Melanoma 18

Interventions

Dutasteride 3acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2proxalutamide 1polyphenon E 1mirabegron 1TroVax 1Transurethral Resection of Prostate 1Transurethral Resection of Bladder 1Therapeutics 1Tamsulosin 1Standard of Care 1Risedronic Acid 1Radiotherapy 1Psychiatric Rehabilitation 1Prostatectomy 1Papaverine 1Oxygen 1Nitrous Oxide 1Needles 1Microspheres 1Lycopene 1Levofloxacin 1Finasteride 1Electroacupuncture 1Doxazosin 1Docetaxel 1Diclofenac 1Dexmedetomidine 1Cystoscopy 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Prostatic Hyperplasia × Docetaxel × Clear all
NCT01194960 2020-10-19

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Oxford BioMedica

Phase 2 Terminated
25 enrolled
Genitourinary

Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡